Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/28/2025

Anticoagulation Therapy for Central and Peripheral Pulmonary Embolism

Initial Treatment Decision

  • The European Society of Cardiology recommends that patients with non-high-risk pulmonary embolism (hemodynamically stable) be treated with direct oral anticoagulants (DOACs) instead of vitamin K antagonists (VKAs) 1, 2
  • If a DOAC is contraindicated (e.g., severe renal insufficiency, pregnancy, breastfeeding, or antiphospholipid syndrome), a VKA (e.g., warfarin) with overlapping parental anticoagulation should be prescribed until an INR value of 2.5 (range 2.0-3.0) is reached for at least 2 consecutive days 1, 3
  • For patients with increased bleeding risk or severe renal insufficiency, unfractionated heparin with an aPTT target range of 1.5-2.5 times the normal value can be recommended as initial treatment 4

Dosage Scheme for DOACs

  • The recommended initial dose of Rivaroxaban is 15 mg twice daily for 3 weeks, followed by 20 mg once daily 2
  • The recommended initial dose of Apixaban is 10 mg twice daily for 7 days, followed by 5 mg twice daily 2

Treatment Duration

  • A minimum of 3 months of therapeutic anticoagulation is recommended for all patients with pulmonary embolism 5
  • For patients with a first pulmonary embolism due to a transient/reversible risk factor, anticoagulation can be stopped after 3 months 5
  • For patients with recurrent venous thromboembolism (VTE), indefinite oral anticoagulation is recommended 5

Special Considerations

  • For patients with active cancer, treatment with low-molecular-weight heparin (LMWH) for at least 3-6 months is recommended, followed by treatment with LMWH or VKA as long as the disease is considered active 5, 6
  • For patients with antiphospholipid syndrome, indefinite oral anticoagulation with VKA is recommended 5

Follow-up and Monitoring

  • Regular checks of medication tolerance, adherence, liver and kidney function, and bleeding risk should be performed in patients with extended anticoagulation 5, 7
  • A routine follow-up examination should be performed 3-6 months after acute pulmonary embolism 2, 7

Anticoagulation Therapy for Pulmonary Embolism

Primary Recommendation: Apixaban as First-Line

  • Direct oral anticoagulants like apixaban are recommended over traditional enoxaparin/warfarin therapy for non-high-risk pulmonary embolism, according to the European Heart Journal 8
  • Apixaban demonstrated non-inferiority to enoxaparin/warfarin for preventing recurrent VTE (relative risk 0.84, 95% CI 0.60-1.18) while showing significantly less major bleeding (relative risk 0.31, 95% CI 0.17-0.55, P<0.001) 9

Specific Indications for Enoxaparin Over Apixaban

  • Patients with cancer should receive indefinite anticoagulation due to high recurrence risk, with low molecular weight heparin (enoxaparin) as the preferred treatment for at least 3-6 months, as recommended by the European Heart Journal 8
  • After 3-6 months of LMWH, transition to oral anticoagulants may be considered on a case-by-case basis depending on cancer status and bleeding risk, according to the European Heart Journal 8
  • Vitamin K antagonists with initial enoxaparin bridging (not apixaban) are recommended for indefinite anticoagulation in patients with antiphospholipid syndrome, as stated in the European Heart Journal 8
  • The American College of Cardiology recommends against using apixaban in cancer patients without careful consideration, as LMWH remains the evidence-based standard 8
  • The European Heart Journal recommends against using apixaban in antiphospholipid syndrome, as this is an absolute indication for VKA therapy 8

Dosing When Apixaban is Chosen

  • When apixaban is appropriate, the recommended regimen is 10 mg twice daily for 7 days, followed by 5 mg twice daily, as stated in the European Heart Journal 9

REFERENCES